Pulmonal sarcoidosis:: A rare side effect of interferon-α treatment for chronic hepatitis C infection
Pulmonal sarcoidosis:: A rare side effect of interferon-α treatment for chronic hepatitis C infection
复制标题
DOI：
10.1055/s-2000-10023
复制
发表时间：
2000-12-01
影响因子：
1.3
通讯作者：
Kallinowski, B
中科院分区：
文献类型：
--
作者：
Pohl, J;Stremmel, W;Kallinowski, B
This is a case report of a 44-year-old woman who received a 1-year-treatment with interferon-alpha for chronic hepatitis C virus infection. 3 months after cessation of the therapy she relapsed and was successfully retreated 12 months with a combination of interferon-alpha and ribavirin thereafter. During the treatment the patient developed a typical flue-like syndrome, dry cough with exertional dyspnea that was initially interpreted as a typical side effect of interferon-alpha treatment. Due to the persisting cough, further radiologic and histologic work up was done and results were significant for interstitial sarcoidosis. After interferon-treatment was stopped the pulmonary symptoms resolved completely while pathologic changes in radiographic imaging persisted. Interferon-alpha may have contributed to the development and progression of sarcoidosis by activation of cellular immunity. Although there are only few reports about pulmonary sarcoidosis associated with interferon-alpha treatment, this entity should be included in the differential diagnosis of putative side effects of interferon-alpha therapy.
